iBio, CC-Pharming Expand Collaboration in China

Licenses to iBio’s Bio-Better Rituximab and FastPharming™ System expand commercial partnership

iBio, Inc. has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (iBio Rituximab) product candidates for the territory of China. In addition, the company will grant to CC-Pharming a research license to iBio’s FastPharming System and know-how for the evaluation of multiple product opportunities.   The companies are jointly pursuing the medical and business goal of introducing a bio-bett...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters